Assessing the prevalence of non-medical prescription opioid use in the Canadian general adult population: evidence of large variation depending on survey questions used

BMC Psychiatry

Jürgen Rehm⁴  Benedikt Fischer³  Anca Ialomiteanu¹  Kevin D Shield² 

[1] Centre for Addiction and Mental Health (CAMH), 33 Russell Street, Toronto, Ontario, M5S 2S1, Canada;Institute of Medical Sciences (IMS), University of Toronto, Toronto,, Ontario, Canada;Centre for Applied Research in Mental Health and Addiction, Simon Fraser University, Faculty of Health Sciences, Vancouver, British Columbia, Canada;Institute for Clinical Psychology and Psychotherapy, Technische Universität Dresden, Chemnitzer Str. 46, Dresden, Germany

关键词: Morbidity;    General population;    Surveillance;    Non-medical use;    Prescription Opioids;   

Others  :  1124187
DOI  :  10.1186/1471-244X-13-6

 received in 2012-03-08, accepted in 2012-12-27,  发布年份 2013

【 摘 要 】

Background

Morbidity and mortality related to Prescription Opioid Analgesics (POAs) have been rising sharply in North America. Non-Medical Prescription Opioid Use (NMPOU) in the general population is a key indicator of POA-related harm, yet the role of question item design for best NMPOU prevalence estimates in general population surveys is unclear, and existing NMPOU survey data for Canada are limited.

Methods

We tested the impact of different NMPOU question items by comparing an item in the 2008 and 2009 (N = 2,017) samples of the CAMH Monitor surveys – an Ontario adult general population survey – with a newly developed item used in the 2010 (N = 2,015) samples of the Centre for Addiction and Mental Health (CAMH) Monitor surveys. To control for a potential difference in the population demographics between surveys, we adjusted for gender, age, region, income, prescription opioid use, cigarette smoking, weekly binge drinking, cannabis use in the past three months, and psychological distress in our analyses.

Results

The prevalence of NMPOU as measured by the 2008 and 2009 CAMH monitor (2.0% [95% CI: 1.2% to 2.8%]) was significantly different when compared to the prevalence of NMPOU as measured by the 2010 CAMH monitor (7.7% [95% CI: 6.3% to 9.2%]) (p < 0.001). This difference was also found when stratifying our analysis by sex (p < 0.001) and when adjusting for all potential confounding covariates.

Conclusion

It is highly unlikely that the extensive NMPOU prevalence differences observed from the different survey items reflect an actual increase of NMPOU or changes in NMPOU determinants, but rather point to measurement effects. It appears that we currently do not have accurate estimates of NMPOU in the Canadian general population, even though these estimates are needed to guide and implement targeted interventions. Given the current substantial morbidity and mortality impact of NMPOU, there is an urgent need to systematically develop, validate and standardize NMPOU items for future general population surveys in Canada.

【 授权许可】

   
2013 Shield et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]International Narcotics Control Board: Narcotic Drugs: Estimated World Requirements for 2012 - Statistics for 2010. Vienna, Austria: International Narcotics Control Board; 2012.
• [2]Fischer B, Argento E: Prescription opioid related misuse, harms, diversion and interventions in Canada: a review. Pain Physician 2012, 15(3 Suppl):ES191-ES203.
• [3]Dhalla IA, Mamdani MM, Sivilotte ML, Kopp A, Qureshi O, Juurlink DN: Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ 2009, 181(12):891-896.
• [4]Manchikanti L: National drug control policy and prescription drug abuse: facts and fallacies. Pain Physician 2007, 10:399-424.
• [5]Fischer B, Rehm J: Deaths related to the use of prescription opioids. CMAJ 2009, 181(12):881-882.
• [6]CfD C: Prevention: vital signs:overdoses of prescription opioid pain relievers –- United States, 1999–2008. MMWR Morb Mortal Wkly Rep 2011, 60(43):1487-1492.
• [7]Compton WM, Volkow ND: Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend 2006, 81:103-107.
• [8]Zacny J, Bigelow G, Compton P, Foley K, Iguchi M, Sannerud C: College on problems of drug dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend 2003, 69:215-232.
• [9]Fischer B, Rehm J: Nonmedical use of prescription opioids: furthering a meaningful research agenda. J Pain 2008, 9(6):490-493.
• [10]Health Canada: Canadian Alcohol and Drug Use Monitoring Survey 2008: microdata user guide. Ottawa: Health Canada; 2009.
• [11]Fischer B, Nakamura N, Ialomiteanu A, Boak A, Rehm J: Assessing the prevalence of non-medical prescription opioid use in the general Canadian population: methodological issues and questions. CAN J Psychiatry 2010, 55(9):606-609.
• [12]Substance Abuse Mental Health Services Administration: Results from the 2008 National Survey on Drug use and Health: National Findings vol. SMA 09–4434. Rockville, MD: SAMHSA Office of Applied Studies; 2009.
• [13]Wisniewski AM, Purdy CH, Bondell RD: The epidemiologic association between opioid prescribing, non-medical use, and emergency department visits. J Addict Dis 2008, 27(1):1-11.
• [14]Ialomiteanu A, Adlaf E: CAMH Monitor 2008 TECHNICAL GUIDE. Toronto: Centre for Addiction and Mental Health; 2009.
• [15]Ialomiteanu A, Adlaf E: CAMH Monitor 2009 TECHNICAL GUIDE. Toronto: Centre for Addiction and Mental Health; 2010.
• [16]Ialomiteanu A, Adlaf E: CAMH Monitor 2010 TECHNICAL GUIDE. Toronto: Centre for Addiction and Mental Health; 2011.
• [17]Paglia-Boak A, Mann RE, Adlaf EM, Rehm J: Drug use among Ontario students, 1977–2009: Detailed OSDUHS findings. Toronto, ON: Centre for Addiction and Mental Health; 2009.
• [18]Goldberg DP, Hillier VF: A scaled version of the general health questionnaire. Psychol Med 1979, 9:139-145.
• [19]Rao JNK, Scott AJ: On simple adjustments to chi-squared tests with sample survey data. Ann Stat 1987, 15:385-397.
• [20]R. Development Core Team: R: A Language and Environment for Statistical Computing (version 2.13.0). Vienna, Austria: R Foundation for Statistical Computing; 2011.
• [21]Lumley T: Analysis of complex survey samples. J Stat Softw 2004, 9(8):1-19.
• [22]Ontario Ministry of Finance: Ontario Population Projections Update 2010–2036. Toronto, Canada: Ontario Ministry of Finance; 2011.
• [23]Johnson TP, Frendrich M, Sudman S, Wislar J, Severns E: An experiment to improve drug use reports during survey interviews. In 1998 Proceedings of the Section on Survey Research Methods edn. Alexandria, VA: American Statistical Association; 1999:888-893.
• [24]Tourangeau R, Yan T: Sensitive questions in surveys. Psychol Bull 2007, 133(5):859-883.
• [25]Strack F, Martin LL: Thinking, judging, and communicating: a process account of context effects in attitude surveys. In Social Information Processing and Survey Methodology. Edited by Hippler HJ, Schwarz N, Sudman S. New York: Springer-Verlag; 1987:123-148.
• [26]Morgan SG, Raymond C, Mooney D, Martin D: The Canadian Rx Atlas. 2nd edition. Vancouver, BC: UBC Centre for Health Services and Policy Research; 2008.
• [27]Substance Abuse Mental Health Services Administration: Results from the 2010 National Survey on drug use and health: detailed tables. Rockville, Maryland: Substance Abuse and Mental Health Services Administration; 2011.
• [28]Shield KD, Ialomiteanu A, Fischer B, Mann RE, Rehm J: Non-medical use of prescription opioids among Ontario adults: data from the 2008/2009 CAMH monitor. Can J Public Health 2011, 102(5):330-335.
• [29]Bruneau J, Roy E, Arruda N, Zang G, Jutras-Aswad D: The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction 2012, 107(7):1318-1327.
• [30]Shield K, Rehm J: Difficulties with telephone-based surveys on alcohol in high-income countries: the Canadian example. Int J Method Psych 2012, 21(1):17-28.
• [31]Fischer B, Rehm J, Goldman B, Popova S: Non-medical use of prescription opioids and public health in Canada. An urgent call for research and interventions development. Can J Public Health 2008, 99(3):182-184.